Loss of p16INK4a expression is frequently observed in lung cancers (Kratzke et al, 1996), and while inactivation may occur by other mechanisms such as point mutations or homozygous deletions, aberrant methylation is the most frequent method. This evidence concerns the gene CDKN2A and lung carcinoma.